Evidence map›Paper›PMID 32087348›Full record

ArticleJournal of hepatology2020

Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12.

Juan P Arab, Daniel Cabrera, Tejasav S Sehrawat, Nidhi Jalan-Sakrikar, Vikas K Verma, Douglas Simonetto, Sheng Cao, Usman Yaqoob, Jonathan Leon, Mariela Freire and 11 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Lipid Droplet Dynamics in Alcoholic Steatohepatitis.The American journal of pathology · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. FTO-mediated mClinical and translational medicine · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Potential prognostic biomarker SERPINA12: implications for hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Foods (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Juan P ArabDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Daniel CabreraDepartamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile; Departamento de Ciencias Químicas y Biológicas, Universidad Bernardo O Higgins, Santiago, Chile.
Tejasav S SehrawatDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Nidhi Jalan-SakrikarDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Vikas K VermaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Douglas SimonettoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Sheng CaoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Usman YaqoobDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Jonathan LeonDepartamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Mariela FreireDepartamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Jose I VargasDepartamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Thiago M De AssuncaoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Jung H KwonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Yi GuoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Enis KostallariDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Qing CaiDepartment of Pathology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.
Tatiana KisselevaDepartment of Surgery, University of California-San Diego, San Diego, CA, USA.
Youngman OhDepartment of Pathology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.
Marco ArreseDepartamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Robert C HuebertDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Vijay H ShahDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Electronic address: shah.vijay@mayo.edu.
Mayo Clinic in Arizona · USPontificia Universidad Católica de Chile · CLVirginia Commonwealth University Medical Center · USUniversity of California, San Diego · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Nicholas F. LaRusso · 2009 to 2026
$22.2M
Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)R37AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH · 2019 to 2026
$3.0M
Molecular Mechanisms of Cholestatic FibrogenesisR01DK117861 · NIDDK · MAYO CLINIC ROCHESTER · PI Robert Christian Huebert · 2019 to 2026
$2.8M
Molecular Mechanisms of Liver FibrosisR01AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2012 to 2018
$2.5M
Molecular Mechanisms of Portal HypertensionR56DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H · 2007 to 2007
$378k
NIAAA NIH HHS R01 AA021171NIAAA NIH HHS R37 AA021171NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK059615NIDDK NIH HHS R01 DK117861NIDDK NIH HHS R56 DK059615
6 · The paper itself

Abstract

BACKGROUND &

aimsSteatohepatitis drives fibrogenesis in alcohol-related liver disease. Recent studies have suggested that hepatic stellate cells (HSCs) may regulate the parenchymal cell injury and inflammation that precedes liver fibrosis, although the mechanism remains incompletely defined. Neuropilin-1 (NRP-1) and synectin are membrane proteins implicated in HSC activation. In this study, we disrupted NRP-1 and synectin as models to evaluate the role of HSC activation on the development of steatohepatitis in response to alcohol feeding in mice.

methodsMice with HSC-selective deletion of NRP (Col

resultsCol

conclusionSelective deletion of NRP-1 from HSCs attenuates alcohol-induced steatohepatitis through regulation of Igfbp3 and SerpinA12 signaling. LAY SUMMARY: Hepatic stellate cells are known for their role in fibrosis (scarring of the liver). In this study, we describe their role in the modulation of fat deposition and inflammation in the liver, which occurs secondary to alcohol damage.

Indexed as

Fatty Liver, AlcoholicAdaptor Proteins, Signal TransducingAnimalsDisease Models, AnimalFibrosisHepatic Stellate CellsInflammationInsulin-Like Growth Factor Binding Protein 3MiceNeuropilin-1Serine Proteinase InhibitorsSerpinsSignal TransductionAdaptor Proteins, Signal TransducingGipc1 protein, mouseInsulin-Like Growth Factor Binding Protein 3Neuropilin-1Serine Proteinase InhibitorsSerpinsAlcoholAlcoholic hepatitisAlcoholic liver diseaseHepatic stellate cellIgfbp3Insulin-like growth factor-binding protein 3IntegrinNeuropilin-1SerpinA12Src-kinaseSteatohepatitisSteatosisVaspin

Identifiers

PMID32087348
PMCPMC7305991
OpenAlexW3007786743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.